Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that dupilumab treatment in alopecia areata significantly suppressed Th2-related markers and increased hair keratin levels, suggesting a potential role of Th2 cytokines in the disease's pathogenesis.

This review highlights that T cells are crucial in regulating hair follicle regeneration and their disruption can lead to alopecia, providing insights into hair disorders related to T cell immune balance and hair follicle regeneration.

This study observed significant differences in immune cell infiltration and gene expression across different skin sites, with the back displaying higher tolerance-promoting immune mechanisms, which may enhance epicutaneous immunotherapy outcomes.

This study found that both Th1 and Th2 immune responses, along with IL-23 and IL-32 cytokine pathways, are active in alopecia areata lesions, and corticosteroid injections significantly altered these immune markers.

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.

This study suggests that IL-4 and IL-13 may play a role in the immunopathogenesis of alopecia areata in some patients, indicating a possible Th2-driven pathway in this condition.

In this study, researchers found that cytokine dysregulation linked to genetic background is present in both patients and healthy but genetically related individuals in two autoimmune skin diseases, Pemphigus vulgaris and Alopecia areata, suggesting that protective immune mechanisms may prevent disease manifestation in predisposed individuals.

This study observed that patients using dupilumab for atopic dermatitis or chronic rhinosinusitis with nasal polyps may experience new-onset or worsening paradoxical alopecia areata, potentially due to unopposed Th1/Th17 immune activity following Th2 pathway blockade.

This case report details the development of a psoriasiform rash and inflammatory alopecia in a 29-year-old man with severe atopic dermatitis following dupilumab treatment. The authors observed hair regrowth and eczema control after discontinuing dupilumab and beginning treatment with abrocitinib.

This study conducted a meta-analysis of gene expression data from alopecia areata patients, identifying 5109 differentially expressed genes and highlighting enriched pathways like JAK-STAT signaling, providing insights into the disease's pathogenesis and potential treatment targets.

Alopecia areata patients are more likely to develop keloids, especially if they also have atopic dermatitis.

This study observed that some patients experienced alopecia areata during dupilumab treatment for atopic dermatitis, but many regrew hair while continuing therapy.

This study found that epidermal growth factor receptor inhibitors used in cancer treatment induce a distinct inflammatory response in hair follicles, marked by immune privilege collapse and upregulation of inflammatory pathways.

Dupilumab can help regrow hair in alopecia areata but stopping it may cause hair loss again.

This study suggests that targeting specific immune pathways, such as IL-12/23 and Th2 cytokines, may offer new treatment options for alopecia areata, a T-cell-mediated disease without current mechanism-specific therapies.

This study found that in patients with alopecia areata and atopic dermatitis, 61.5% showed improvement with dupilumab treatment, but 38.5% experienced worsened or new-onset alopecia areata, with higher baseline IgE levels linked to better responses.

In this study, the researchers found that deleting ceramide synthase 4 in the skin's epidermis alters stem cell differentiation, disrupting hair follicle structure and barrier function, potentially leading to immune responses similar to atopic dermatitis.

This study conducted a scoping review and meta-analysis revealing a complex chemokine profile in alopecia areata patients, with elevated Th1, Th2, and other immune pathway chemokines, suggesting broader immunomodulatory strategies may help address the disease's multifaceted immune dysregulation.

In this scoping review and meta-analysis, researchers found that patients with alopecia areata exhibit complex chemokine profiles, with elevated levels of Th1, Th2, and other immune pathway-associated chemokines, suggesting the potential for broad immunomodulatory strategies to address the disease's immune dysregulation.

In this scoping review and meta-analysis, researchers found that patients with alopecia areata show a complex serum chemokine profile, predominantly involving Th1- and Th2-associated chemokines, suggesting that broader immunomodulatory strategies might address the diverse immune dysregulation observed in the disease.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

In this single-cell transcriptomic study, researchers analyzed AA scalp samples and found distinct immune and nonimmune cell activation patterns, with elevated TH1/TH2 and JAK/STAT markers potentially contributing to hair follicle immune privilege disruption and disease severity.

This review examines the interconnected processes of atopic dermatitis and alopecia areata, highlighting shared immune imbalances, genetic factors, and microbiome influences, while analyzing current and emerging treatments and identifying gaps in understanding these overlapping conditions.

This case study reported that Dupilumab treatment improved eczema, itch, and hair condition in a girl with Netherton Syndrome, as shown by over 40% improvement in various dermatological scores; however, significant flares of ichthyosis linearis circumflexa persisted.

In this retrospective study, researchers found a statistically significant increase in the risk of alopecia areata among atopic dermatitis patients using dupilumab compared to controls, suggesting the need for careful monitoring and further research on the drug's impact on alopecia areata.

In this case report, researchers documented a 71-year-old woman with both alopecia areata and bullous pemphigoid who showed significant improvement using dupilumab after other treatments failed, highlighting its potential for autoimmune diseases with overlapping inflammatory mechanisms.

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.

This review discusses natural remedies and nanoparticle formulations for alopecia management and reports no new clinical results, emphasizing potential benefits of herbal treatments over synthetic therapies.

Targeting immune pathways like JAK/STAT may help treat frontal fibrosing alopecia.

In this study, topical naringin was found to significantly improve dermatitis severity and reduce inflammatory markers in a mouse model of atopic dermatitis, suggesting its potential as a therapeutic agent for this condition.